Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

So we know that the recent discovery Jonah Sacha m

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153778
(Total Views: 903)
Posted On: 12/09/2024 11:53:56 AM
Posted By: ohm20
Re: MGK_2 #148501
Quote:
So we know that the recent discovery Jonah Sacha made using bNAbs, ART and leronlimab led to the non-development of any reservoirs of HIV despite HIV inoculation. It also led to the eradication of HIV for 1.25 years following inoculation.

My question is regarding LATCH. The patients slated for this protocol would have failed ART and so have developed a significant reservoir of HIV. Would a stem cell transplant eradicate the reservoir in the recipient patient?

How would the same be achieved using AAV?



In LATCH the patients would not have to have failed ART treatment. Of course reservoirs exist whether or not ART has failed. Reservoirs are not eradicated by stem cell transplants but they seem to be lowered. My theory is that reservoirs release HIV in response to lowered active HIV in the body, as far as I know that has never been tested. It would explain how maraviroc and by extension leronlimab decreases the number of reservoirs.

In stem cell transplants involving CCR5 double allele 32 delta deletion donors and in some cases single allele the patients original immune system is wiped out and is replaced by the donors CCR5 deletion genetics. There would be no active HIV reproduction due to lack of expressed CCR5 or in the case of leronlimab by blockade. This gives the immune system the chance to kill off the relatively few HIV viruses released from reservoirs.

The only difference between subcutaneous leronlimab and AAV is that no lapses in coverage would be due to missed or misapplied injections (possibly the cause of HIV viral rebounds in trials) and AAV leronlimab levels may surpass 750mg which would still provide 100% receptor binding in the case of a sharp rise in CCR5 expression due to other immune challenges.


(14)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us